Dosing for Healthcare Professionals

 

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease before a scheduled procedure

THE RIGHT DOSE TO TARGET THE RIGHT RESPONSE

DOPTELET® (avatrombopag) Scheduling Calculator

Use the Scheduling Calculator to plan for your patient's upcoming procedure and start DOPTELET. Please choose one of the options below. 

Enter Procedure Date
to generate a range of dates to start DOPTELET

 

OR

Enter DOPTELET Start Date
to generate a range of dates to schedule procedure

 
   

Two dosing options based on your patient’s baseline platelet count1

40 mg (2 tablets) DOPTELET is taken once daily

High-Baseline
Platelet Count 40×109/L to <50×109/L

40 mg (2 tablets) once daily with food

40 mg (2 tablets) DOPTELET is taken once daily

Low-Baseline
Platelet Count <40×109/L

60 mg (3 tablets) once daily with food

Start DOPTELET® (avatrombopag) 10 to 13 days prior to a scheduled procedure1

 DOPTELET Dosing Guide

Monitoring: Obtain a platelet count prior to administration of DOPTELET, and on the day of a procedure, to ensure an adequate increase in platelet count.

Dova® 1Source™

Committed to helping patients navigate access to their prescribed therapy

Dova 1Source can help your prescribed patients navigate access at any point through the fulfillment process.

Reference:

1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was 1 treatment-emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTELET should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

Contraindications: None

Adverse Reactions

The most common adverse reactions (≥3%) were: pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.

 

Please see Full Prescribing Information for DOPTELET® (avatrombopag).

Visit Dova.com for WAC pricing.

 
 

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was 1 treatment-emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with DOPTELET. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).